<DOC>
	<DOC>NCT00234403</DOC>
	<brief_summary>The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer</brief_summary>
	<brief_title>A Trial to Evaluate the Combination of Iressa &amp; FaslodexÂ® in Patients With Advanced or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirmed advanced or metastatic breast cancer postmenopausal females with amenorrhoea &gt; 12 months and an intact uterus FSH levels within postmenopausal range or have undergone a bilateral oophorectomy ER &amp;/or PR positive previous adjuvant hormone therapy &gt; 12 months prior to enrolment previous adjuvant chemotherapy &gt; 6 months prior to enrolment measurable disease according to RECIST and/or non measurable bone disease life expectancy of at least 12 weeks World Health Organisation (WHO) performance status (PS) of 0 to 1. Male lifethreatening metastatic visceral disease evidence of clinically active interstitial lung disease ER and PR negative treatment with LHRH analogues &lt; 3 months prior to enrolment patients who have restarted menses or do not have FSH levels within the postmenopausal range treatment with strontium 90 (or other radio pharmaceutical) within the previous 3 months Treatment with hormonotherapy and/or chemotherapy for advanced disease extensive radiotherapy to measurable lesions within the last 4 weeks (i.e. &gt;30% of bone marrow, e.g. whole of pelvis or half of spine) currently receiving oestrogen replacement therapy treatment with a nonapproved or experimental drug within 4 weeks before enrolment absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than 100 x 109/L , serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR, serum creatinine greater than 1.5 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases, or greater than 5 times the ULRR in the presence of liver metastases, history of bleeding diathesis or long term or present anticoagulant therapy (other than antiplatelet therapy any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, known severe hypersensitivity to ZD1839 or fulvestrant or any of the excipients of this product.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>ER positive breast cancer</keyword>
	<keyword>PR positive breast cancer</keyword>
</DOC>